Topics

Companies Related to "Study investigate surrogate decision challenges LGBT patients with" [Most Relevant Company Matches] RSS

17:27 EST 25th January 2020 | BioPortfolio

Here are the most relevant search results for "Study investigate surrogate decision challenges LGBT patients with" found in our extensive corporate database of over 50,000 company records.

Showing "Study investigate surrogate decision challenges LGBT patients with" Companies 1–25 of 5,600+

Relevant

Be the Partner

Be the Partner provides technology that makes clinical trials a better experience and gains patient insights beyond the trial. Our platform enables data sharing and communication between de-identified study participants and pharmaceutical companies. We partner with industry and work closely with patients and clinical research sites to better understand the...


L.A. Gay & Lesbian Center

Since 1971 the L.A. Gay & Lesbian Center has been building the health, advocating for the rights and enriching the lives of lesbian, gay, bisexual and transgender people. Our wide array of services and programs includes: free HIV/AIDS care and medications for those most in need; housing, food, clothing and support for homeless LGBT youth; low-cost counseling and addiction-recovery services; essent...

Point Foundation

Point Foundation (Point) is the nation's largest scholarship-granting organization for lesbian, gay, bisexual and transgender (LGBT) students of merit. Point provides financial support, leadership training, mentoring and hope to LGBT individuals who are marginalized because of their sexual orientation, gender identity or gender expression. Point provides its scholars with the financial ability to ...


Dr.ROBERT SCALES

Robert Scales, Ph.D., is a native of Scotland, but he has resided in the Southwest for the past twenty years. He has his doctorate degree in education and he holds a faculty position in the School of Medicine at the University of New Mexico, where he conducts research and teaches motivational interviewing (MI). Currently, he is the Director of Cardiac Rehabilitation and Wellness at a hospital in...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Guildford Clinical Pharmacology

Guildford Clinical Pharmacology Ltd (GCPL) has wide experience of efficient study designs in Phases 1 & 2 and develops new surrogate markers especialy for analgesics, the CNS and gastrointestinal drugs. We can use high tech equipment and the staff to run it correctly; recent examples being: 1) Gamma cameras for colonic transit measurements in a proof of efficacy study on a morphine antagonist an...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

MVA Scientific Consultants

The scientific challenges facing today’s businesses and organizations are diverse and complex. Environmental concerns, legal and regulatory issues, increased operating performance and customer expectations are just some of the issues where science can impact the way business is done.MVA Scientific Consultants helps to meet some of these challenges by providing critical analysis and support ...

Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

APPLIED DECISION CONCEPTS, LLC

APPLIED DECISION CONCEPTS, LLC combines clinical acumen, scientific expertise and academic rigor to provide state-of-the-art research and consultative services to help decision makers answer questions regarding clinical efficacy, economic impact, and cost-effectiveness of various medical interventions and programs. APPLIED DECISION CONCEPTS, LLC is unique in that we continue to maintain an active ...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Vitrolife AB (publ)

The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been ...

Parkinson's Institute

The Institute is an independent, not-for-profit organization conducting patient care and research activities in the neurological specialty area of movement disorders. Our mission is to find the cause and cure for these disorders, to provide the best available medical care to patients with movement disorders, to investigate better treatment and diagnostic tools, and to develop prevention strategies...

Annexon Biosciences

Annexon’s pipeline of novel therapies includes two clinical-stage product candidates, ANX005, a monoclonal antibody, and ANX007, a fragmented monoclonal antibody, as well as other compounds in preclinical development. ANX005 is currently in a Phase 1/2 study in patients with Guillain-Barre Syndrome (GBS). Annexon also plans to evaluate ANX005 in complement-mediated neurodegenerative disorder...

Imara, Inc.

Imara, Inc. is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 has been specifically designed to treat patients with sickle cell disease by bot...

Kyruus Inc.

Kyruus is a health care Big Data company that provides solutions to health care organizations seeking to meet the unique challenges of today’s regulatory and economic environment. As providers adapt to critical operational, financial, and clinical challenges, Kyruus enables effective integration of disparate data sets in order to guide institutional d...

medCPU Inc. and UPMC

As a leader in decision support, New York-based medCPU develops and markets medCPU Advisor, an intelligent decision support solution that uses precise technology, extensive content, and robust services to deliver real-time alerts that improve quality, safety, efficiency, and costs. The medCPU Advisor technology addresses healthcare IT challenges of inte...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's imm...

Quantum Vision Centers

Quantum Vision Centers and Eye Surgery Center have taken steps to address this incident and to protect patients’ personal information from further unauthorized access, including by working diligently to contain the promulgation of the malware, and engaging a third-party forensics firm to investigate the scope and source of the incident. They also deployed back up measures to recover the data...


More From BioPortfolio on "Study investigate surrogate decision challenges LGBT patients with"

Quick Search

Corporate Database Quicklinks